<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Findings from three trials evaluating chemo plus trastuzumab versus trastuzumab followed by chemo in HER2-positive metastatic breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Findings from three trials evaluating chemo plus trastuzumab versus trastuzumab followed by chemo in HER2-positive metastatic breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Findings from three trials evaluating chemo plus trastuzumab versus trastuzumab followed by chemo in HER2-positive metastatic breast cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">HERTAX (n = 101)<sup>[1]</sup></td> <td class="subtitle1">JO17360 (n = 112)<sup>[2]</sup></td> <td class="subtitle1">SAKK 22/99 (n = 175)<sup>[3]</sup></td> </tr> <tr> <td><strong>Treatment schema</strong></td> <td>Tr + Doc (comb)<br/> versus<br/> Tr → Doc (seq)</td> <td>Tr + Doc (comb)<br/> versus<br/> Tr → Tr + Doc (seq)</td> <td>Tr + chemo (comb)<br/> versus<br/> Tr → Tr + chemo (seq)</td> </tr> <tr> <td><strong>Line of treatment</strong></td> <td>First line</td> <td>First line</td> <td>First, second, or third line</td> </tr> <tr> <td><strong>Median first PFS during Tr monotherapy</strong></td> <td>3.9 mo</td> <td>3.7 mo</td> <td>3.7 mo</td> </tr> <tr> <td><strong>Median PFS or TTP following both Tr and chemo</strong></td> <td>PFS 9.4 mo (comb)<br/> versus<br/> PFS 9.9 mo (seq)</td> <td>PFS 14.6 mo (comb)<br/> versus<br/> PFS 12.4 mo (seq)</td> <td>TTP 10.3 mo (comb)<br/> versus<br/> TTP 12.2 mo (seq)</td> </tr> <tr> <td><strong>RECIST RR following both Tr and chemo</strong></td> <td>58 (comb)<br/> versus<br/> 38% (seq)</td> <td>67.9 (comb)<br/> versus<br/> 47.2% (seq)</td> <td>Not reported</td> </tr> <tr> <td><strong>Median OS</strong></td> <td>30.5 mo (comb)<br/> versus<br/> 19.7 mo (seq)</td> <td>Not reached, but HR 2.72 with p = 0.04 in favor of comb</td> <td>36.3 mo (comb)<br/> versus<br/> 35.6 mo (seq)</td> </tr> <tr> <td><strong>Trial caveats</strong></td> <td>Tr was not continued along with docetaxel in the sequential arm</td> <td>Study closed early due to presumption of inferiority of sequential arm at interim analysis</td> <td>Accrual over 13 years; many censored patients due to off protocol endocrine therapy added; study design changed during conduct; chemo regimens not reported</td> </tr> </tbody></table></div><div class="graphic_footnotes">Tr: trastuzumab; Doc: docetaxel; comb: combination; seq: sequential; PFS: progression-free survival; mo: month; TTP: time to tumor progression; RECIST: Response Evaluation Criteria in Solid Tumors; RR: response rate; OS: overall survival; HR: hazard ratio.</div><div class="graphic_reference">References: 

<ol>
<li>Hamberg P, Bos MM, Braun HJ, et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011; 11:103.</li>
<li>Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010; 119:127.</li>
<li>Pagani O, Klingbiel D, Ruhstaller T, et al. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Ann Oncol 2017; 28:305.</li></ol></div><div id="graphicVersion">Graphic 113438 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
